Praziquantel Ameliorates CCl4 -induced Liver Fibrosis in Mice by Inhibiting TGF-β/Smad Signalling via Upregulating Smad7 in Hepatic Stellate Cells.
Praziquantel (PZQ) is a schistosomicide which has been used for more than 30 years due to its efficiency, safety and mild side effects. Previous studies showed that the prolonged treatment with PZQ could suppress the development of liver fibrosis in schistosomiasis mice. In this study, we investigated the potential mechanisms underlying the antifibrotic role of PZQ. To avoid the impact of schistosomicidal activity of PZQ against liver fibrosis induced by S. japonicum infection, we established a mouse model of carbon tetrachloride (CCl4 )-induced liver fibrosis for in vivo studies and used TGF-β1-stimulated human hepatic stellate cell line (LX-2) in addition to other fibroblast-like cell line (MES13) and fibroblast cell line (NIH3T3) in vitro. Western blotting, immunohistochemistry, qRT-PCR, siRNA and immunofluorescence staining were utilized to assess the expression of key molecules in liver fibrosis and the TGF-β/Smad pathway. PZQ administration significantly attenuated CCl4 -induced liver fibrosis through the inhibition of hepatic stellate cells (HSCs) activation and collagen matrix expression via enhancement of Smad7 expression, which were confirmed in LX-2, MES13 and NIH3T3 cells in vitro. In contrast, knockdown of Smad7 in LX-2 cell prevented PZQ mediated inhibition of LX-2 cell activation and TGF-β1-meidated collagen type I α1 induction, revealing the critical role of Smad7 in the antifibrotic effect of PZQ during liver fibrosis. PZQ exhibited a strong efficacy against liver fibrosis by inhibiting HSCs activation via Smad7 upregulation, suggesting is potential broad utility in treatment of diseases characterized by liver fibrosis.